PSM led a coalition of organizations urging leaders of the Senate HELP and House Energy and Commerce committees to help strengthen the FDAs ability to protect Americans from unsafe and counterfeit medicines and medical products
One-week treatment of DIO mice with G49 induces a transient lipid overload in the liver, increases ketogenesis and FGF21 levels Due to the rapid increase (16 h) in circulating FFAs in G49-treated mice (Fig
Per brand-published materials, compounded medications are prepared using ingredients sourced from FDA-regulated suppliers - though the compounded product itself is not FDA-reviewed or approved

Ozempic label, AccessFDA Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system, Frontiers in Public Health (2022) Gastrointestinal tolerability of onceweekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss, Diabetes, Obesity, and Metabolism (2021) Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss, JAMA Network (2023) Constipation, Penn State College Medicine Foods for constipation, Johns Hopkins Medicine Exercise therapy in patients with constipation: A systematic review and meta-analysis of randomized controlled trials, Scandinavian Journal of Gastroenterology (2019) Bowel retraining, National Library of Medicine (2022) Concerned about constipation